HOXC Cluster Antisense RNA 3, a Novel Long Non-Coding RNA as an Oncological Biomarker and Therapeutic Target in Human Malignancies

Yunhe Xie¹,², Jiarong Ye³, Hongliang Luo¹

¹Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330008, People’s Republic of China; ²Department of General Surgery, Jiujiang Hospital of Traditional Chinese Medicine, Jiujiang, Jiangxi, 332007, People’s Republic of China; ³Queen Mary School, Nanchang University, Nanchang, Jiangxi, 330038, People’s Republic of China

Correspondence: Hongliang Luo, Department of Gastrointestinal Surgery, the Second Affiliated Hospital of Nanchang University, No. 1 Minde Road, Nanchang, Jiangxi Province, 330008, People’s Republic of China, Tel +86 13097280001, Email 13097280001@163.com

Abstract: HOXC cluster antisense RNA 3 (HOXC-AS3) is a novel long noncoding RNA (lncRNA) that exhibits aberrant expression patterns in various cancer types. Its expression is closely related to clinicopathological features, demonstrating significant clinical relevance across multiple tumors. And HOXC-AS3 plays multifaceted roles in tumor progression, impacting cell proliferation, apoptosis, migration, invasion, epithelial-mesenchymal transition (EMT), autophagy, senescence, tumor growth, and metastasis. In this review, we summarized and comprehensively analyzed the expression and clinical significance of HOXC-AS3 as a diagnostic and prognostic biomarker for malignancies. Additionally, we presented an in-depth update on HOXC-AS3’s functions and regulatory mechanisms in cancer pathogenesis. This narrative review underscores the importance of HOXC-AS3 as a promising lncRNA candidate in cancer research and its potential as a predictive biomarker and therapeutic target in clinical applications.

Keywords: long non-coding RNA, HOXC-AS3, malignant neoplasms, neoplastic processes, biological marker

Introduction

In recent years, the discovery and characterization of long non-coding RNAs (lncRNAs) have greatly advanced our understanding of the non-coding transcriptome and its relevance to human diseases, particularly cancer.¹⁻⁴ Dysregulation of lncRNAs has been implicated in disease onset and progression, and their functional investigations have unveiled their essential role in various molecular processes, including cell growth, cell cycle, autophagy, and metabolism.⁵⁻⁷ Consequently, lncRNAs have emerged as novel disease targets for clinical applications, driven by an increased in-depth understanding of their functions and molecular mechanisms.

Among these lncRNAs, HOXC cluster antisense RNA 3 (HOXC-AS3) has garnered significant attention due to its dysregulated expression patterns observed in multiple malignancies.¹¹⁻¹⁷ A number of studies have revealed the implication of HOXC-AS3 expression in a range of human cancers, and elevated HOXC-AS3 expression has been correlated with clinicopathologic characteristics such as tumor grade, size, metastasis, and TNM stage and prognosis.¹⁷⁻²² Research has further unveiled the regulatory effects of HOXC-AS3 on the initiation and progression of diverse human tumors, involving modulation of cellular processes such as cell proliferation, apoptosis, invasion, metastasis, and metabolic reprogramming.¹¹⁻¹⁵ HOXC-AS3 exhibits promising potential for diagnostic, prognostic, and therapeutic applications.¹¹⁻¹⁵,¹⁷,²¹,²²

To gather relevant literature for the comprehensive synthesis of HOXC-AS3’s role in cancer biology and its potential clinical relevance. We systematically searched databases, including PubMed, Web of Science, and Google Scholar, using keywords “HOXC-AS3” and “HOXC cluster antisense RNA 3”. Articles published in English up to August 1, 2023, were considered, and sources were included based on predefined criteria, focusing on studies investigating the expression, clinicopathological correlations, biological functions, and clinical implications of HOXC-AS3 in various human tumor types.
This review aims to provide a thorough overview of HOXC-AS3’s expression profiles, clinicopathologic features, biological roles, molecular mechanisms, and clinical implications across different tumor types. By consolidating existing knowledge, it aims to contribute to our integrated understanding of HOXC-AS3’s significance as a compelling lncRNA candidate in cancer research, paving the way for its potential clinical applications in cancer management.

**Characteristics of HOXC-AS3**

Homo sapiens HOXC-AS3 is classified as a non-coding RNA (ncRNA) gene type. It is located on the reverse strand of Chromosome 12 at coordinates 53,983,951 to 53,985,519, spans three exons, and has a length of 1569 nucleotides (nt) [source: https://www.ncbi.nlm.nih.gov/gene/100874365]. HOXC-AS3 is a natural antisense transcript of HOXC10. LncRNAs generated within HOX genes have been documented to play pivotal roles in tumorigenesis. For example, HOXA11-AS, an antisense transcript of HOXA11, has been identified as an oncogenic lncRNA in various cancer types. Another well-known oncogenic lncRNA, HOTAIR, originates from the antisense strand of HOXC11. Notably, HOXC-AS3 is situated within the HOX gene cluster, sharing the genomic location 12q13.13 with HOTAIR. This association suggests a potential role for HOXC-AS3 in tumor formation and progression.

HOXC-AS3 has been detected in both the cytoplasm and nucleus in most reported tumor cells, with more prominent expression in the cytoplasm of glioma cells. Experimental and bioinformatic analyses have confirmed HOXC-AS3 as a classic lncRNA with no coding potential, emphasizing its role solely as a lncRNA. Consequently, the observed functions are attributed exclusively to the lncRNA itself. Furthermore, the Minimum Free Energy (MFE) secondary structure, a widely recognized model commonly used for understanding RNA stability and potential functional roles, was predicted for HOXC-AS3 using the RNAfold web server (http://rna.tbi.univie.ac.at/cgi-bin/RNAWebSuite/RNAfold.cgi?PAGE=3&ID=zB2AoN9m89), as illustrated in Figure 1.

**Expression of HOXC-AS3 and Its Clinical Value as a Novel Biomarker for Human Cancer**

Numerous studies have demonstrated the dysregulation of HOXC-AS3 in different human tumors, along with its association with clinicopathological characteristics and patients’ clinical outcomes (Table 1). This section provides an overview and investigates the alterations in HOXC-AS3 expression, its correlation with clinicopathologic features, and its clinical potential as a promising biomarker in various tumors.

**Transcriptomic Patterns of HOXC-AS3 in Bulk Tissues**

HOXC-AS3 has emerged as a promising candidate involved in many biological processes, such as development, differentiation, and tumorigenesis. In order to gain a deeper understanding of its potential roles in physiological contexts, an integrated assessment of its expression across diverse normal human tissues was performed with the extensive transcriptomic data available in the Genotype-Tissue Expression (GTEx) project (https://www.gtexportal.org/) (Figure 2A and B). The expression of HOXC-AS3 varies greatly in different tissues, with relatively high expression in the kidney, skin, and testis, and relatively low expression in most human tissues (Figure 2A and B). The higher expression in kidney and skin tissues may indicate an important role of HOXC-AS3 in the development and homeostasis of these organs. Likewise, the relatively higher expression in the testis may imply its contribution to spermatogenesis or reproductive processes. In short, the observed tissue-specific expression patterns of HOXC-AS3 may provide clues to its potential biological regulation of tissue development and function relevant to cancer research.

**Expression Profile of HOXC-AS3 in Malignancies**

Abnormal HOXC-AS3 expression has been reported in various human malignant tissues, including gastric cancer, nasopharyngeal carcinoma, glioma, breast cancer, ovarian cancer, cervical cancer, hepatocellular carcinoma, colorectal cancer, lung cancer and mesenchymal stromal cells (MSCs) derived from multiple myeloma (MM) patients (Table 1). To comprehensively explore the expression profile of HOXC-AS3 in human pan-cancer, we assessed HOXC-AS3 expression levels in 33 cancer types using UCSC XENA (https://xenabrowser.net/datapages/) (Figure 3A–C).
The results showed that HOXC-AS3 was significantly up-regulated in several malignancies of the digestive and respiratory systems (Figure 3A), including esophageal carcinoma (ESCA), liver hepatocellular carcinoma (LIHC), pancreatic adenocarcinoma (PAAD), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), and genitourinary and gynecologic cancers (Figure 3B), such as adrenocortical carcinoma (ACC), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), and uterine corpus endometrial carcinoma (UCEC). Conversely, HOXC-AS3 was notably down-regulated in kidney chromophobe (KICH), kidney renal clear cell carcinoma (KIRC), and testicular germ cell tumors (TGCT) (Figure 3B).

These differential expression patterns across various cancer types suggest that HOXC-AS3 expression levels may have significant clinical relevance in predicting disease onset and progression.

**Clinical Significance of HOXC-AS3 in Tumors**

**HOXC-AS3 as a Prognostic Marker**

HOXC-AS3 expression levels have been determined to correlate with clinical features of various cancers, see Table 1 for details. High expression of HOXC-AS3 in tumor samples showed a significant positive correlation with clinicopathological features, including tumor grade, metastasis, and TNM stage. Furthermore, the relationship between HOXC-AS3 expression and patient prognosis was investigated in several studies (Table 1). HOXC-AS3 displayed different prognostic significance in different cancer types. In most of the reported tumors, including gastric cancer, glioma, breast cancer, and cervical cancer,
<table>
<thead>
<tr>
<th>Cancer Type</th>
<th>Model Used (Sample Size; Detection Method)</th>
<th>Expression</th>
<th>Clinical Characteristics</th>
<th>Survival (p-value)</th>
<th>Biomarker</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gastric cancer</td>
<td><strong>17</strong> Human Tissues (112 pairs of cancer and non-cancerous tissues; qRT-PCR), GEO (GSE50710, 10 cancer, 110 normal; and GSE58828, 3 cancer, 3 normal), TCGA (data from TANRIC) (285 cancer, 33 normal)</td>
<td>Up-regulated</td>
<td>Histological grade, tumor invasion depth, lymph node metastasis, TNM stage</td>
<td><strong>OS (p&lt;0.05)</strong></td>
<td>Prognostic</td>
</tr>
<tr>
<td>Gastric cancer</td>
<td><strong>23</strong> GEO dataset (5 paired gastric cancer and adjacent tissues)</td>
<td>Up-regulated</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Gastric cancer</td>
<td><strong>23</strong> TCGA (343 tumor samples and 30 normal samples)</td>
<td>Up-regulated</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Nasopharyngeal carcinoma</td>
<td><strong>34</strong> Human tissues (30 nasopharyngeal carcinoma and 27 chronic nasopharyngitis tissues, IncRNA RNA sequencing)</td>
<td>Up-regulated</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Glioblastoma</td>
<td><strong>31</strong> TCGA dataset (Glioblastoma and normal tissue RNA sequencing data)</td>
<td>Up-regulated</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Glioma</td>
<td><strong>16</strong> Human tissues (15 normal brain tissues and 23 glioma tissues; qRT-PCR), TCGA (169 glioma tissues and 5 normal tissues), GEPIA database (159 glioma patients)</td>
<td>Up-regulated</td>
<td>–</td>
<td><strong>OS (p=0.0023)</strong></td>
<td>Prognostic</td>
</tr>
<tr>
<td>Breast cancer</td>
<td><strong>20</strong> TCGA (837 cancer, 105 normal)</td>
<td>Up-regulated</td>
<td>–</td>
<td><strong>OS (p=0.031)</strong></td>
<td>Prognostic</td>
</tr>
<tr>
<td>Breast cancer</td>
<td><strong>19</strong> Human Tissues (60 pairs of cancer and non-cancerous tissues; qRT-PCR), TCGA (1054 cancer, 98 normal)</td>
<td>Up-regulated</td>
<td>Cancer subgroups, TNM stage, lymph node metastasis</td>
<td><strong>DFS (p=0.001)</strong></td>
<td>Prognostic</td>
</tr>
<tr>
<td>Breast cancer</td>
<td><strong>11</strong> Human tissues (83 cases of fresh breast cancer tissues; qRT-PCR), GEO (13 cancer, 44 normal), TANIC (837 cancer, 105 normal), GEPIA (1085 cancer, 291 normal), TCGA (1109 cancer, 113 normal)</td>
<td>Up-regulated</td>
<td>Molecular subtypes, lymph node metastasis, pTNM stage, ER status, HER2 status</td>
<td><strong>OS (p&lt;0.05)</strong></td>
<td>Prognostic/ Diagnostic ROC of LNM (Area= 0.8013); ROC of pTNM (Area= 0.8315)</td>
</tr>
<tr>
<td>Ovarian cancer</td>
<td><strong>35</strong> Human tissues (62 pairs of cancer and non-cancerous tissues; qRT-PCR)</td>
<td>Up-regulated</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Cervical cancer</td>
<td><strong>36</strong> Human tissues (36 pairs of cancer and non-cancerous tissues; qRT-PCR), GEPIA Database (306 cancer, 13 normal)</td>
<td>Up-regulated</td>
<td>FIGO stage, tumor size</td>
<td><strong>OS (p=0.073), DFS (p=0.014)</strong></td>
<td>Prognostic</td>
</tr>
<tr>
<td>Hepatocellular carcinoma</td>
<td><strong>15</strong> Human tissues (75 pairs of cancer and non-cancerous tissues; qRT-PCR), TCGA Database-The StarBase (v3.0) (1150 cancer, 141 normal)</td>
<td>Up-regulated</td>
<td>–</td>
<td><strong>OS (p=0.00021)</strong></td>
<td>Prognostic</td>
</tr>
<tr>
<td>Colorectal cancer</td>
<td><strong>13</strong> Human tissues (63 pairs of tumor and non-tumor tissues; qRT-PCR)</td>
<td>Down-regulated</td>
<td>–</td>
<td><strong>OS (p&lt;0.05)</strong></td>
<td>Prognostic</td>
</tr>
<tr>
<td>Colorectal cancer</td>
<td><strong>37</strong> Human tissues (39 pairs of tumor and non-tumor tissues; qRT-PCR)</td>
<td>Up-regulated</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Non-small cell lung cancer</td>
<td><strong>14</strong> Human tissues (30 pairs of tumor and non-tumor tissues; qRT-PCR)</td>
<td>Up-regulated</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Non-small cell lung cancer</td>
<td><strong>13</strong> Human tissues (62 pairs of tumor and non-tumor tissues; qRT-PCR)</td>
<td>Up-regulated</td>
<td>T stages, lymph nodes metastasis, distant metastasis, clinical stage</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Multiple myeloma</td>
<td><strong>20</strong> Human tissues (7 tumor patients and 7 normal donors; qRT-PCR)</td>
<td>Up-regulated</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

**Abbreviations:** qRT-PCR, real-time reverse transcription-polymerase chain reaction; OS, overall survival; DFS, disease-free survival.
hepatocellular carcinoma, HOXC-AS3 overexpression tends to predict poor prognosis, whereas in colorectal cancer (CRC), high expression of HOXC-AS3 indicates good prognosis.

Moreover, apart from the aforementioned cancer types, we also evaluated the correlation between HOXC-AS3 and the prognosis of various other forms of cancer, based on the TCGA dataset available at (https://portal.gdc.cancer.gov/).

Our investigation encompassed overall survival (OS), disease-specific survival (DSS), and disease-free interval (DFI) for these additional cancer types (Figure 4A). Kaplan–Meier (KM) plots analysis results further showed that HOXC-AS3 expression level was significantly correlated with the prognosis of patients with ACC, Glioblastoma multiforme (GBM), and Skin cutaneous melanoma (SKCM) (Figure 4B). High expression of HOXC-AS3 indicated worse OS, DSS, and DFI in ACC, shorter OS, and DSS in GBM, while better OS, DSS, and DFI in SKCM (Figure 4B). These findings indicate that HOXC-AS3 holds distinct prognostic implications across various cancer types, making it a potentially valuable prognostic indicator for a range of malignancies.

HOXC-AS3 as a Cancer Diagnostic Biomarker

Moreover, receiver operating characteristic (ROC) curve analysis revealed that HOXC-AS3 could be used as a potent diagnostic biomarker in multiple cancer types (Figure 5A), particularly in Pheochromocytoma and paraganglioma (PCPG), ESCA, SKCM, and TGCT, where the area under the curve (AUC) exceeded 0.9 (Figure 5B). These results indicate that HOXC-AS3 has the potential to act as a valuable diagnostic marker in a wide range of tumors.
HOXC-AS3 is involved in regulating biological functions and cancer progression through a series of mechanisms, including cell proliferation, apoptosis, migration, invasion, epithelial-mesenchymal transition (EMT), autophagy, senescence, tumor growth, metastasis, and osteogenic differentiation (Table 2 and Figure 6). It has demonstrated significant regulatory roles in multiple cancers, such as breast cancer and non-small cell lung cancer. HOXC-AS3 holds promise as a novel therapeutic target for human cancers.

HOXC-AS3 is distributed in both cytoplasm and nucleus, exerting crucial modulatory roles at transcriptional and post-transcriptional levels. LncRNAs can act as negative regulators of miRNA biogenesis, revealing a novel mechanism.
Figure 4 The relationship between HOXC-AS3 expression and OS/DSS/PFI in different cancers from TCGA (A) and KM curves showed the significant prognostic value of HOXC-AS3 overexpression in ACC, GBM, and SKCM (B).

Abbreviations: ACC, Adrenocortical carcinoma; PCPG, Pheochromocytoma and paraganglioma; BLCA, Bladder urothelial carcinoma; DLBC, Diffuse large B-cell lymphoma; ESCA, Esophageal carcinoma; GBM, Glioblastoma multiforme; HNSC, Head and neck squamous cell carcinoma; KICH, Kidney chromophobe; KIRC, Kidney renal clear cell carcinoma; KIRP, Kidney renal papillary cell carcinoma; LUAD, Lung adenocarcinoma; LUSC, Lung squamous cell carcinoma; MESO, Mesothelioma; SARC, Sarcoma; PAAD, Pancreatic adenocarcinoma; SKCM, Skin cutaneous melanoma; TGCT, Testicular germ cell tumors; UCEC, Uterine corpus endometrial carcinoma; UCS, Uterine carcinosarcoma.
of lncRNA-miRNA crosstalk.\textsuperscript{38–41} HOXC-AS3 has been reported to suppress the maturation of miR-96 by inhibiting the transportation of premature miR-96 from the nucleus to the cytoplasm in ovarian and lung cancer cells.\textsuperscript{13,35}

One crucial lncRNA mechanism is acting as a competing endogenous RNA (ceRNA),\textsuperscript{42–44} sequestering miRNAs from their target mRNAs and forming a lncRNA-miRNA-mRNA network. Several studies have shown HOXC-AS3 could functions as a ceRNA by interacting with miRNAs, including miR-216 in glioma,\textsuperscript{16} miR-3922-5p\textsuperscript{20} and miR-1224-5p in breast cancer,\textsuperscript{11} miR-105-5p in cervical cancer,\textsuperscript{36} miR-1269 in colorectal cancer.\textsuperscript{12} Additionally, several assays, including luciferase reporter, RNA immunoprecipitation (RIP), and RNA pull-down, have identified miRNA binding sites on HOXC-AS3. Functional assays demonstrated that miRNAs and their target mRNAs regulate HOXC-AS3’s effects.

Moreover, a growing body of evidence reveals the regulatory mechanisms of lncRNAs include regulating transcriptional or splicing regulation and interaction with RNA-binding proteins.\textsuperscript{45–47} Here, HOXC-AS3 can interact with

---

**Figure 5** Diagnostic ROC curves of HOXC-AS3 expression for differentiating tumor from normal tissue in pan-cancer (A) using UCSC XENA datasets, and HOXC-AS3 expression showed strong diagnostic value in PCPG, ESCA, SKCM, and TGCT (B).

**Abbreviations:** AUC, Area under the curve; ACC, Adrenocortical carcinoma; PCPG, Pheochromocytoma and paraganglioma; BLCA, Bladder urothelial carcinoma; BRCA, Breast invasive carcinoma; CESC, Cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, Cholangiocarcinoma; COAD, Colon adenocarcinoma; READ, Rectum adenocarcinoma; DLBC, Diffuse large B-cell lymphoma; LAML, Acute myeloid leukemia; ESCA, Esophageal carcinoma; GBM, Glioblastoma multiforme; LGG, Brain lower grade glioma; HNSC, Head and neck squamous cell carcinoma; KICH, Kidney chromophobe; KIRC, Kidney renal clear cell carcinoma; KIRP, Kidney renal papillary cell carcinoma; LIHC, Liver hepatocellular carcinoma; LUAD, Lung adenocarcinoma; LUSC, Lung squamous cell carcinoma; SARC, Sarcoma; OV, Ovarian serous cystadenocarcinoma; PAAD, Pancreatic adenocarcinoma; PRAD, Prostate adenocarcinoma; SKCM, Skin cutaneous melanoma; STAD, Stomach adenocarcinoma; TGCT, Testicular germ cell tumors; THCA, Thyroid carcinoma; HNSC, Head and neck squamous cell carcinoma; UCEC, Uterine corpus endometrial carcinoma; UCS, Uterine carcinosarcoma.
proteins, including YBX1, SIRT6, CDK2, and FUS, further influencing tumorigenesis. HOXB13 can upregulate HOXC-AS3 expression by binding to its promoter region, exerting malignant potential in glioblastoma. RNA-RNA interactions can alter RNA's secondary or tertiary structure, shielding it from RNase degradation and enhancing its stability. LncRNA HOXC-AS3 interacts with HOXC10 to form an RNA-RNA structure, reducing HOXC10 RNA decay, and subsequently up-regulating the expression of HOXC10. For different malignant tumors, the detailed molecular mechanisms underlying HOXC-AS3’s regulatory effects are discussed in the following sections.

<table>
<thead>
<tr>
<th>Cancer Type</th>
<th>Role</th>
<th>Experiment</th>
<th>Function</th>
<th>Action Mechanism of HOXC-AS3</th>
<th>Related Molecule/Signal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gastric cancer</td>
<td>Oncogenic</td>
<td>In vitro and in vivo</td>
<td>Proliferation, migration, apoptosis, metastasis</td>
<td>Interact with protein</td>
<td>H3K4me3, H3K27ac, YBX1, MMP7, WNT10B, and HDAC5</td>
</tr>
<tr>
<td>Glioblastoma</td>
<td>Oncogenic</td>
<td>In vitro</td>
<td>Proliferation, migration, invasion</td>
<td>Binding to promoter</td>
<td>HOXB13</td>
</tr>
<tr>
<td>Glioma</td>
<td>Oncogenic</td>
<td>In vitro and in vivo</td>
<td>Proliferation, migration, invasion, tumor growth</td>
<td>As a ceRNA</td>
<td>miR-216, F11R</td>
</tr>
<tr>
<td>Breast cancer</td>
<td>Oncogenic</td>
<td>In vitro and in vivo</td>
<td>Invasion and migration, EMT, metastasis</td>
<td>As a ceRNA</td>
<td>miR-3922-5p, PPP1R1A</td>
</tr>
<tr>
<td>Breast cancer</td>
<td>Oncogenic</td>
<td>In vitro and in vivo</td>
<td>Proliferation and migration, apoptosis, tumor growth</td>
<td>Interact with protein</td>
<td>YBX1, TK1</td>
</tr>
<tr>
<td>Breast cancer</td>
<td>Oncogenic</td>
<td>In vitro and in vivo</td>
<td>Metabolic reprogramming, proliferation, migration, invasion, tumor growth, metastasis</td>
<td>As a ceRNA</td>
<td>H3K9ac, SIRT6, HIF1α, PFK1, PDK4, LDHA, SP1, miR-1224–5p</td>
</tr>
<tr>
<td>Ovarian cancer</td>
<td>Oncogenic</td>
<td>In vitro</td>
<td>Proliferation, apoptosis, autophagy, senescence</td>
<td>Regulate microRNA maturation</td>
<td>miR-96, MacroH2A, HP1, Caspase9, LC3-B, P53</td>
</tr>
<tr>
<td>Cervical cancer</td>
<td>Oncogenic</td>
<td>In vitro and in vivo</td>
<td>Proliferation, apoptosis, migration, invasion, tumor growth, metastasis</td>
<td>As a ceRNA</td>
<td>miR-105-5p, ErbB signaling pathway (SOS1/Raf/MEK/ERK)</td>
</tr>
<tr>
<td>Hepatocellular carcinoma</td>
<td>Oncogenic</td>
<td>In vitro and in vivo</td>
<td>Proliferation, cell cycle, tumor growth</td>
<td>Interact with protein</td>
<td>CDK2, p21, Rb</td>
</tr>
<tr>
<td>Colorectal cancer</td>
<td>Suppressive</td>
<td>In vitro</td>
<td>Migration, invasion</td>
<td>As a ceRNA</td>
<td>miR-1269, TGF-β2</td>
</tr>
<tr>
<td>Invasive mucinous adenocarcinoma of the lung</td>
<td>Oncogenic</td>
<td>In vitro</td>
<td>Proliferation, migration, apoptosis</td>
<td>Interact with protein</td>
<td>FUS, FOXM1</td>
</tr>
<tr>
<td>Non-small cell lung cancer</td>
<td>Oncogenic</td>
<td>In vitro and in vivo</td>
<td>Proliferation, migration, invasion, tumor growth, metastasis</td>
<td>Interact with protein</td>
<td>YBX1, HOXCB, MDM2</td>
</tr>
<tr>
<td>Non-small cell lung cancer</td>
<td>Oncogenic</td>
<td>In vitro</td>
<td>Cell invasion, migration</td>
<td>Regulate microRNA maturation</td>
<td>miR-96</td>
</tr>
<tr>
<td>Multiple myeloma</td>
<td>Oncogenic</td>
<td>In vitro and in vivo</td>
<td>Osteogenic differentiation</td>
<td>RNA-RNA interaction</td>
<td>HOXC10</td>
</tr>
</tbody>
</table>

Table 2 The Role and Regulatory Mechanism of lncRNA HOXC-AS3 in Multiple Human Malignancies
Gastrointestinal Tract System Tumors
Gastric Cancer
HOXC-AS3 exhibits high expression in gastric cancer tissues, and its overexpression is associated with a dismal prognosis. In addition, HOXC-AS3 expression serves as an independent predictor of OS and TNM stage in gastric cancer patients. Elevated HOXC-AS3 expression levels are also observed in gastric cancer cell lines, including...
BGC823, SGC-7901, MGC-803, and SNU-601. Functional studies involving ASO-mediated knockdown and plasmid-mediated overexpression reveal that HOXC-AS3 regulates gastric cancer cell proliferation and migration in vitro, while also influencing tumor growth and lung metastasis in mouse xenograft models. Mechanistically, lncRNA HOXC-AS3 participates in the tumorigenesis of gastric cancer by binding to YBX1, thereby modulating the transcriptional regulation of several target genes, including MMP7, WNT10B, and HDAC5.

Colorectal Cancer
Enteghami et al first detected HOXC-AS3 expression in CRC and found that it was higher in CRC tumor tissue compared to adjacent normal tissues, although not significantly altered. Interestingly, HOXC-AS3 was significantly positively correlated with the well-known oncogenic lncRNA HOTAIR, but negatively correlated with HOXC10. In a subsequent study by Zhang et al, HOXC-AS3 was reported to be significantly downregulated in CRC tissues and CRC cell lines. The observed differences in HOXC-AS3 expression in CRC tissues may be attributed to the ethnicity of the individuals in these two studies. Zhang et al also found that low HOXC-AS3 levels were indicative of poor survival in CRC patients. Notably, HOXC-AS3 overexpression effectively impedes TGF-β2-induced migration and invasion in CR4 and RKO colorectal cancer cells by acting as a sponge for miR-1269. This is of significance as a positive feedback loop between TGF-β signaling and miR-1269 has been reported to promote metastasis in colorectal cancer.

Hepatocellular Carcinoma
In hepatocellular carcinoma, HOXC-AS3 is highly expressed in cancer tissues and is observed in five cancer cell lines (97H, HLF, HepG2, Hep3B and PLC/PRF/5), and it has been associated with poor overall survival. In terms of biological functions, HOXC-AS3 has been demonstrated, through in vitro and in vitro experiments, to promote the proliferation in cells and facilitate tumor proliferation and growth in tumor xenograft models. The interaction of HOXC-AS3 with CDK2 reduces CDK2’s binding to p21, thereby enhancing CDK2 activity. This results in increased RB phosphorylation, promoting cell cycle progression from G1 to S-phase, ultimately enhancing cell proliferation, and advancing the progression of hepatocellular carcinoma.

Gynecologic System Tumors
Ovarian Cancer
HOXC-AS3 has been found to be upregulated in ovarian cancer compared to paired non-neoplastic tissues. To assess its effects, a CCK-8 assay and apoptosis assay were conducted, revealing that HOXC-AS3 overexpression led to increased cell proliferation while reducing cell apoptosis in Caov3 and OVCAR3 cells. Additionally, changes in the expression of apoptosis, senescence, and autophagy-related proteins upon the addition of HOXC-AS3 indicated its involvement in these cellular behaviors of ovarian cancer cells. A study by Vera et al showed that HOXC-AS3 was significantly upregulated in cisplatin-resistant ovarian cancer cells, suggesting its potential biological significance in cisplatin resistance in ovarian cancer. Furthermore, HOXC-AS3 may be implicated in the ivermectin-mediated lncRNA-EIF4A3-mRNA pathways in ovarian cancer.

Cervical Cancer
HOXC-AS3 is up-regulated in cervical cancer tissues and cancer cell lines (CaSki, SiHa, HeLa, ME180, and C33A). Overexpression of HOXC-AS3 has been associated with higher FIGO stage, larger tumor size, and poorer prognosis in cervical cancer. HOXC-AS3 exerts carcinogenic effects by enhancing proliferation, anti-apoptosis, migration, invasion, tumor growth, and metastasis. LncRNA HOXC-AS3 exacerbates cervical cancer progression and metastasis by up-regulating SOS1 expression level through miR-105-5p sequestration, further activating the ErbB signaling pathway.

Other Tumors
Glioma
Glioma is the most prevalent primary brain tumor, with glioblastomas as grade IV astrocytomas exhibiting the highest aggressiveness and mortality in adults. HOXC-AS3 has shown a significant increase in glioma tissues compared to normal brain tissues and is highly expressed in glioma cell lines (U87, U25, T98G, LN229, and A172) compared to
normal human astrocytes (NHAs). Additionally, the expression level of HOXC-AS3 was found to be inversely correlated with the prognosis of glioma patients. Furthermore, HOXC-AS3 could facilitate glioma cell proliferation, migration, invasion, and tumor growth by upregulating F11R expression through sponging miR-216 or participate in HOXB13-induced glioblastomas cell proliferation, migration, and invasion.

**Breast Cancer**

It was found that the expression of HOXC-AS3 in breast cancer tissue was significantly higher than in normal breast tissue. Similarly, the expression of HOXC-AS3 in breast cancer cells (SK-BR-3, MDA-MB-231, HCC-1954, T47D, MDA-MB-468) was also markedly elevated than in normal mammary epithelial cell line (MCF-10A). In addition, HOXC-AS3 has demonstrated potential as a promising prognostic marker in breast cancer. Both in vivo and in vitro studies have provided evidence that HOXC-AS3 contributes the breast cancer progression by regulating cell proliferation, migration, apoptosis, epithelial-mesenchymal transition, tumor growth, metastasis, and metabolic reprogramming. Mechanistically (Figure 7), HOXC-AS3 regulates breast cancer progression by directly transcriptionally activating TK1 by binding to YBX1 or promoting breast cancer metastasis by upregulating PPP1R1A expression as a miR-3922-5p sponge. Furthermore, it has been reported that overexpression of HOXC-AS3 induced by low glucose levels promotes metabolic reprogramming in breast cancer. The HOXC-AS3/SP1/miR-1224–5p axis forms a positive feedback loop that enhances its cancer-promoting roles (Figure 7).

**Non-Small Cell Lung Cancer**

Non-small cell lung cancer (NSCLC), accounting for about 80–90% of all lung cancer cases, mainly includes squamous cell carcinoma and adenocarcinoma. Within adenocarcinoma, invasive mucinous adenocarcinoma (IMA) is classified as a unique histologic subtype of lung adenocarcinoma. The role of HOXC-AS3 in lung cancers has been reported. In a study by Yang et al, HOXC-AS3 was found to be approximately two- to-eight-fold up-regulated in IMA cell lines (A549, SPC-A1, H441, H1299) compared with the non-cancer cell line HBE. Knock-down of HOXC-AS3 inhibited the proliferation and migration of IMA cells and promoted apoptosis. Mechanistically (Figure 8), HOXC-AS3 enhances the stability of FOXM1 mRNA and promotes the expression of FOXM1 by recruiting FUS (Figure 8), thereby accelerating cell proliferation, migration and inhibiting cell apoptosis in IMA. FUS is a well-known RNA binding protein (RBP) that acts as an mRNA stabilizer recruited by lncRNAs. In NSCLC, HOXC-AS3 was significantly elevated in NSCLC tissues and also remarkably upregulated in NSCLC cells (A549, H522, H460, and H1299). The subcellular location of HOXC-AS3 was detected in the cytoplasm and nuclear. HOXC-AS3 over-expression in NSCLC tissues was closely correlated with unfavorable clinical features. In vitro functional assays showed that HOXC-AS3 could promote invasion and migration and enhance cell proliferation. A nude mouse xenograft model demonstrated that knockdown of HOXC-AS3 inhibited NSCLC tumor growth and metastasis in vivo. The oncogenic roles of HOXC-AS3 were achieved by sponging premature miR-96 or by stabilizing YBX1 and thereby increasing HOXC8 transcription (Figure 8).

![Figure 7 Regulatory mechanisms of lncRNA HOXC-AS3 in breast cancer.](https://doi.org/10.2147/OTT.S425523)
Multiple Myeloma

Multiple myeloma (MM) is a hematologic malignancy known to causes severe imbalances in bone remodeling, resulting in serious skeletal lesions. The level of HOXC-AS3 was found to be upregulated in mesenchymal stromal cells (MSCs) derived from MM relative to those from healthy volunteer donors. RNA FISH further showed the presence of HOXC-A3 in the cytoplasm and nucleus of MSCs. Moreover, HOXC-AS3 transcripts were found to positively regulate the expression of HOXC10. Specifically, IncRNA HOXC-AS3 interacts with HOXC10, forming an RNA-RNA structure that protects HOXC10 RNA from degradation by RNase enzymes. This interaction leads to the upregulation of HOXC10 expression, ultimately repressing the osteogenic differentiation of MSCs. This regulatory mechanism has been substantiated through in vivo and in vitro experimental data.

Conclusions and Perspectives

HOXC-AS3 is an emerging IncRNA that exhibits dysregulated expression in various human malignancies. Extensive research has unveiled its valuable clinical significance, owing to its tissue-specific expression patterns and significant clinical relevance in tumors. HOXC-AS3 expression levels were associated with tumor clinical features. For example, in gastric cancer, HOXC-AS3 levels are significantly linked to histological grade, tumor invasion depth, lymph node metastasis, and TNM stage. In breast cancer, HOXC-AS3 expression levels were positively correlated with lymph node metastasis, clinical stage, and different breast cancer subtypes, highlighting its influence on cancer characteristics and behavior. In NSCLC, high HOXC-AS3 expression levels indicated deeper T stages, tumor metastasis, and advanced clinical stages, suggesting its involvement in disease progression and metastasis. Since HOXC-AS3 has been implicated in multiple biological processes, HOXC-AS3 overexpression promotes cell proliferation, migration, invasion, and metastasis, thereby influencing tumor progression and development. The function of HOXC-AS3 on tumors may contribute to understanding the impact of HOXC-AS3 levels on key clinical parameters in various cancers.

Furthermore, HOXC-AS3 holds potential as a dual-purpose biomarker, serving as both a prognostic predictor and a diagnostic marker in various tumors. It exhibits robust prognostic value across different cancer types, offering valuable insights for prognostic prediction and personalized treatment strategies. According to reported studies and analysis of TCGA database data, high expression of HOXC-AS3 in tumor samples generally indicates an unfavorable prognosis, except for CRC and SKCM, where it is associated with a more favorable prognosis. This may involve multiple factors, including the molecular characteristics of cancer, the biology of the disease, and the interactions of HOXC-AS3 with other genes or pathways. Further research is needed to understand these differences. And HOXC-AS3 expression could be also used to distinguish patients with or without lymph node metastases and different tumor stages in breast cancer, and HoxC-AS3’s diagnostic potential for distinguishing between tumor and normal tissue was evaluated using large
online datasets from UCSC XENA. It demonstrated strong diagnostic value across various cancers, with notable effectiveness in PCPG, ESCA, SKCM, and TGCT.

HOXC-AS3 exerts its regulatory effects through molecular mechanisms that involve interactions with microRNAs, leading to the formation of ceRNA networks and modulation of target gene expression. Additionally, HOXC-AS3 has demonstrated interactions with proteins and other non-coding RNAs, as well as binding to the promoters of target genes, thereby exerting regulatory influence at both the transcriptional and post-transcriptional levels. A comprehensive understanding of these regulatory mechanisms is crucial in elucidating the precise roles of HOXC-AS3 and identifying potential therapeutic targets. Moreover, HOXC-AS3 has been implicated in tumor progression and metastasis through several signaling pathways, including the ErbB signaling pathway and metabolic pathways, which have been identified as promising targets for therapeutic interventions in the context of tumor treatment.

In addition, the presence of chemoresistance poses a major obstacle in cancer therapy, hindering the effectiveness of chemotherapy. Recent studies suggest that HOXC-AS3 expression may be associated with chemotherapy response in certain cancers. For example, in ovarian cancer, the inclusion of ivermectin as a treatment option may prove beneficial, as HOXC-AS3 potentially influences the lncRNA-EIF4A3-mRNA pathways regulated by ivermectin. And the significant upregulation of HOXC-AS3 in cisplatin-resistant ovarian cancer cells suggests its potential biological significance in conferring resistance to cisplatin treatment. These studies indicate that targeting HOXC-AS3 could serve as a viable therapeutic strategy to enhance chemosensitivity in cancer.

Despite the progress made in understanding the implications of HOXC-AS3 in human malignancies, several areas require further special attentions. First, in-depth investigations into the underlying molecular mechanisms and signaling pathways regulated by HOXC-AS3 are needed in different cancer types for the development of novel therapeutic strategies. Future studies should focus on identifying small molecules, nucleic acid-based therapeutics, or gene editing approaches that can selectively modulate HOXC-AS3 expression or disrupt its interactions with regulatory molecules. Second, due to the inconvenience and limited accessibility of obtaining HOXC-AS3 from tumor tissue biopsies, it is necessary to further explore the specificity and stability of HOXC-AS3 expression in minimally invasive body fluids, such as blood and urine. Establishing a reliable and non-invasive method to detect and quantify HOXC-AS3 expression levels in the clinical setting will expedite its translation into clinical practice. Third, additional studies are warranted to explore the diagnostic and prognostic value of HOXC-AS3 in larger patient cohorts and across diverse populations. Validation of its potential as a biomarker will provide valuable insights into its utility for personalized cancer management.

In conclusion, the comprehensive understanding of the expression and implications of HOXC-AS3 in human malignancies contributes to our understanding of the non-coding transcriptome and its role in cancer biology. The clinical significance of HOXC-AS3 as a diagnostic and prognostic biomarker, as well as its involvement in diverse cellular processes, underscores its potential as a therapeutic target for cancer management. Further efforts in in vivo studies and clinical trials are necessary to elucidate the detailed mechanisms of HOXC-AS3 and explore its clinical applications. Moreover, future experiments should focus on testing the efficacy and safety of targeted HOXC-AS3 drugs, with the ultimate goal of improving cancer management.

Data Sharing Statement
The data that support the findings of this study are available from the corresponding author upon reasonable request.

Acknowledgment
We thank Xiantao Tools (https://www.xiantaozi.com/) for helping to obtain analysis data datasets from TCGA, Genotype-Tissue Expression (GTEx), and UCSC Xena to evaluate the expression of HOXC-AS3 and its clinical outcome in tumors.

Author Contributions
All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically
reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

**Funding**

This work was supported by the Natural Science Foundation of Jiangxi Province, China (S2020ZRMSB0672).

**Disclosure**

The authors declare that they have no conflicts of interest in this work.

**References**


